79472-22-3

Usage

Uses

Used in Pharmaceutical Industry:
4,5-Dihydrothieno[2,3-c]pyrrol-6-one is used as a pharmaceutical compound for its demonstrated biological activities, such as antifungal, antibacterial, and anticancer properties. Its diverse therapeutic potential makes it a valuable candidate for the development of new drugs to combat various diseases and infections.
Used in Materials Science:
In the field of materials science, 4,5-Dihydrothieno[2,3-c]pyrrol-6-one is utilized as a building block for the synthesis of complex natural products and drug-like molecules. Its unique structural features and reactivity contribute to the creation of novel materials with specific properties for various applications.
Used in Chemical Research and Development:
4,5-Dihydrothieno[2,3-c]pyrrol-6-one serves as an interesting target in chemical research and development due to its unique structure and reactivity. It is studied to understand its properties and to explore its potential in creating new chemical entities and processes that could benefit various industries.

Upstream product

• 61341-26-2 3-methylthenoyl chloride 
• 81452-54-2 methyl 3-methylthiophene-2-carboxylate 
• 59961-15-8 methyl 3-(bromomethyl)thiophene-2-carboxylate 
• 79472-21-2 3-(aminomethyl)thiophene-2-carboxylic acid methyl ester 

Downstream Products

• 957345-85-6 2-bromo-4H,5H,6H-thieno[2,3-c]pyrrol-6-one 

Relevant academic research and scientific papers

METHODS OF TREATING NEURODEGENERATIVE DISEASES

Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

New tetracyclic compound

The invention relates to a new tetracyclic compound. The tetracyclic compound has a structure shown in the formula (III) and can be used as a bromine domain and additional terminal (BET) inhibitor. The invention further relates to synthesis and application of the compounds in disease treatment. More specifically, the invention relates to a fused heterocyclic derivative used as a BET inhibitor, a method for the preparation of these compounds, and a disease and symptom treatment method conductive to inhibition of one or more BET bromine domains.

HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF

The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.

(2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol-5-yl)ketone derivative, preparation and uses thereof

The present invention discloses a (2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol-5-yl)ketone derivative, preparation and uses thereof, and particularly relates to a (2,4-dihydroxy-5-isopropylphenyl)(4,6-dihydro-5H-thieno[2,3-c]pyrrol

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

MST1 KINASE INHIBITORS AND METHODS OF THEIR USE

Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.

IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula ( I ) represented by the following:The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.

Thienopyrrolone substituted benezenesulfonylureas and their use

Sulfonylureas of the formula STR1 wherein R1, X and Y have the indicated meanings, as well as their physiologically acceptable salts, pharmaceutical preparations on the basis of these compounds and their use in the treatment of diabetes.